ESTRELLA IMMUNOPHARMA, INC. Accounts Payable and Other Accrued Liabilities, Current
ESTRELLA IMMUNOPHARMA, INC. (ESLA) had Accounts Payable and Other Accrued Liabilities, Current of $255.56 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Accounts Payable and Other Accrued Liabilities, Current $255.56K.
- 2026-03-31: Accounts Payable and Other Accrued Liabilities, Current $179.08K.
- 2025-12-31: Accounts Payable and Other Accrued Liabilities, Current $238.41K.
- 2025-09-30: Accounts Payable and Other Accrued Liabilities, Current $75.61K.
| Period end | Accounts Payable and Other Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $255.56K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $179.08K 10-Q · filed 2026-05-18 |
| 2025-12-31 | $238.41K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $75.61K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $110.77K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $117.84K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $201.76K 10-K · filed 2026-03-18 |
| 2024-09-30 | $188.98K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $131.82K 10-KT · filed 2025-03-25 |
| 2024-03-31 | $89.41K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $270.58K 10-Q · filed 2024-02-14 |
| 2023-06-30 | $398.78K 10-K · filed 2024-09-27 |
| 2022-06-28 | $10.00M 10-Q · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |